Collectively, our data in two cell line models of mutation-independent TKI-resistance, as well as patient samples, demonstrate a novel pathway connecting NOX2 to the transcription factor early growth response 1 (Egr-1) and subsequently Fyn, highlighting new mediators of TKI-resistance with potential to eradicate cancer stem cells. This evidence concerns the gene EGR1 and cancer.